Cleared Traditional

FERTELL FEMALE FERTILITY TEST (K032002) - FDA 510(k) Clearance

Class I Chemistry device.

K032002 · Genosis, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2003
Decision
125d
Days
Class 1
Risk

K032002 is an FDA 510(k) clearance for the FERTELL FEMALE FERTILITY TEST. Classified as Test, Follicle Stimulating Hormone (fsh), Over The Counter (product code NGA), Class I - General Controls.

Submitted by Genosis, Inc. (Washington, US). The FDA issued a Cleared decision on October 30, 2003 after a review of 125 days - within the typical 510(k) review window.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1300 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all Genosis, Inc. devices

Submission Details

510(k) Number K032002 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 27, 2003
Decision Date October 30, 2003
Days to Decision 125 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
37d slower than avg
Panel avg: 88d · This submission: 125d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code NGA Test, Follicle Stimulating Hormone (fsh), Over The Counter
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1300
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.